Frontlight ResearchEarly access
CompletedNo phase
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
Key facts
- Who runs it
- Yueyue Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,730 people enrolled
- Started
- 1 Jan 2022
- Ended
- 31 Jul 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- Record updated
- 11 September 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- patients aged 18-70 years, regardless of gender
- absent history of receiving H. pylori eradication therapy
- diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination
Who cannot take part
- patients who received treatment regimens that did not comply with the quadruple regimens specified in this study
- patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.
The 2 groups in the trial
- vonoprazan-based quadruple therapies
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- tegoprazan-based quadruple therapies
Treatment: This study is a retrospective study, and all data have been collected in advance with no active intervention required.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Bismuth-containing Quadruple Therapy for First Line Helicobacter Pylori Eradication: A Multicenter Retrospective Study
- Record updated
- 11 September 2025